title: Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors.
abstract: Core-binding factor acute myeloid leukemia (CBF-AML) - including AML with t(8;21) and AML with inv(16) - accounts for about 15% of adult AML and is associated with a relatively favorable prognosis. Nonetheless, relapse incidence may reach 40% in these patients. In this context, identification of prognostic markers is considered of great interest. Due to similarities between their molecular and prognostic features, t(8;21) and inv(16)-AML are usually grouped and reported together in clinical studies. However, considerable experimental evidences have highlighted that they represent two distinct entities and should be considered separately for further studies. This review summarizes recent laboratory and clinical findings in this particular subset of AML and how they could be used to improve management of patients in routine practice.
authors.affiliation: Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Duployez
authors.forename: Christophe
authors.initials: C
authors.lastname: Willekens
authors.forename: Alice
authors.initials: A
authors.lastname: Marceau-Renaut
authors.forename: Elise
authors.initials: E
authors.lastname: Boudry-Labis
authors.forename: Claude
authors.initials: C
authors.lastname: Preudhomme
mesh_terms: D000818:Animals; D050660:Core Binding Factors / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000378:metabolism*; D011379:Prognosis
chemical_list: D050660:Core Binding Factors
keywords: CBFB-MYH11; RUNX1-RUNX1T1; acute myeloid leukemia; core binding factor; minimal residual disease; mutational analysis; prognostic markers.